文献速递白血病

PROTAC MDM2降解剂在原代白血病细胞与PDX模型中的活性

Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models.
PubMed 文献 · Leukemia · 2026-04-15

MD-265是一种招募CRBN降解MDM2的PROTAC,在105例原代白血病干细胞的体外培养中中位细胞毒IC50为16 nM,而MI-1061的中位IC50高150倍。IC50>1 µM的LSCs分类为MD-265耐药并携带TP53突变,正常造血干细胞IC50为818 nM,较LSCs高100倍。在NSG-SGM3小鼠AML PDX模型中,MD-265无毒性并延长生存。

要点

  • MD-265在105例原代LSCs中中位IC50为16 nM,MI-1061中位IC50高150倍。
  • IC50>1 µM的LSCs为MD-265耐药且携带TP53突变。
  • 正常造血干细胞IC50为818 nM,较LSCs高100倍。

核心结论

  • MD-265是强效特异的MDM2降解剂,具有广泛临床前活性,是治疗白血病的 promising 药物候选。

研究设计与样本

  • 在105例原代白血病干细胞(LSCs)体外培养中测试MD-265的细胞毒性。
  • 在NSG-SGM3小鼠AML患者来源异种移植(PDX)模型中,用MD-265或口服MDM2抑制剂治疗。

主要发现

  • MD-265对原代LSCs的中位细胞毒IC50为16 nM,MI-1061的中位IC50高150倍。
  • IC50>1 µM的LSCs分类为MD-265耐药,并携带TP53突变。
  • 正常造血干细胞IC50为818 nM,较LSCs高100倍。
  • 在PDX模型中,MD-265无毒性并延长生存。

关键数值与推荐

  • 原代LSCs中MD-265中位细胞毒IC50为16 nM。
  • MI-1061中位IC50较MD-265高150倍。
  • LSCs IC50>1 µM分类为MD-265耐药。
  • 正常造血干细胞IC50为818 nM,较LSCs高100倍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MDM2 is an E3 ubiquitin ligase that promotes p53 tumor suppressor degradation and has emerged as a therapeutic target in the treatment of wild-type (wt) TP53 tumors. In acute myeloid leukemia (AML), TP53 mutations are infrequent (15-20%), but wt-p53 is often inactivated through overexpression of MDM2. Thus, MDM2 inhibitors are currently in clinical trials for AML. However, p53 stabilization with inhibitors upregulates MDM2, which limits their clinical efficacy. Proteolysis-targeting chimeric (PROTAC) molecules that degrade MDM2 may overcome this feedback. MD-265 is a PROTAC that recruits CRBN, degrades MDM2, restores p53 and induces apoptosis. We tested MD-265 in ex vivo cultures of 105 primary leukemic stem cells (LSCs). The median cytotoxic IC50 for MD-265 was 16 nM, median IC50 for MI-1061 was 150-fold higher. LSCs with IC50 > 1 µM were classified as MD-265 resistant and harbored mutations in TP53. Normal hematopoietic stem cells showed 100-fold higher IC50 (818 nM) than LSCs. AML patient-derived xenograft (PDX) models in NSG-SGM3 mice were treated with MD-265 or an oral MDM2 inhibitor. In PDX models, MD-265 was not toxic and prolonged survival. MD-265 is a potent and specific MDM2 degrader with broad pre-clinical activity and a promising drug candidate for the treatment of leukemias.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kandarpa M, Peterson LF, Potu H, et al. Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models. Leukemia. 2026. PMID: 41986621. doi:10.1038/s41375-026-02957-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。